Literature DB >> 33513340

Optineurin deletion disrupts metabotropic glutamate receptor 5-mediated regulation of ERK1/2, GSK3β/ZBTB16, mTOR/ULK1 signaling in autophagy.

Karim S Ibrahim1, Caitlyn J McLaren2, Khaled S Abd-Elrahman1, Stephen S G Ferguson3.   

Abstract

Optineurin (OPTN) is a multifunctional protein that mediates a network of cellular processes regulating membrane trafficking, inflammatory responses and autophagy. The OPTN-rich interactome includes Group I metabotropic glutamate receptors (mGluR1 and 5), members of the Gαq/11 protein receptor family. Recent evidence has shown that mGluR5, in addition to its canonical Gαq/11 protein-coupled signaling, regulates autophagic machinery via mTOR/ULK1 and GSK3β/ZBTB16 pathways in both Alzheimer's and Huntington's disease mouse models. Despite its potential involvement, the role of OPTN in mediating mGluR5 downstream signaling cascades remains largely unknown. Here, we employed a CRISPR/Cas9 OPTN-deficient STHdhQ7/Q7 striatal cell line and global OPTN knockout mice to investigate whether Optn gene deletion alters both mGluR5 canonical and noncanonical signaling. We find that OPTN is required for mGluR5-activated Ca2+ flux and ERK1/2 signaling following receptor activation in STHdhQ7/Q7 cells and acute hippocampal slices. Deletion of OPTN impairs both GSK3β/ZBTB16 and mTOR/ULK1 autophagic signaling in STHdhQ7/Q7 cells. Furthermore, mGluR5-dependent regulation of GSK3β/ZBTB16 and mTOR/ULK1 autophagic signaling is impaired in hippocampal slices of OPTN knockout mice. Overall, we show that the crosstalk between OPTN and mGluR5 can have major implication on receptor signaling and therefore potentially contribute to the pathophysiology of neurodegenerative diseases.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Autophagy; Ca(2+); GPCR; Optineurin; mGluR5

Mesh:

Substances:

Year:  2021        PMID: 33513340     DOI: 10.1016/j.bcp.2021.114427

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?

Authors:  Rebecca F Budgett; Geor Bakker; Eugenia Sergeev; Kirstie A Bennett; Sophie J Bradley
Journal:  Front Pharmacol       Date:  2022-05-11       Impact factor: 5.988

2.  VGLUT3 Ablation Differentially Modulates Glutamate Receptor Densities in Mouse Brain.

Authors:  Karim S Ibrahim; Salah El Mestikawy; Khaled S Abd-Elrahman; Stephen S G Ferguson
Journal:  eNeuro       Date:  2022-05-09

3.  Neuroprotective Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells From Different Donors on Spinal Cord Injury in Mice.

Authors:  Xu Zhu; Zhen Wang; Yi Eve Sun; Yuchen Liu; Zhourui Wu; Bei Ma; Liming Cheng
Journal:  Front Cell Neurosci       Date:  2022-01-11       Impact factor: 5.505

4.  Impact of Organelle Transport Deficits on Mitophagy and Autophagy in Niemann-Pick Disease Type C.

Authors:  Maik Liedtke; Christin Völkner; Andreas Hermann; Moritz J Frech
Journal:  Cells       Date:  2022-02-01       Impact factor: 6.600

5.  Analysis of immune-related key genes in Alzheimer's disease.

Authors:  You Wu; Shunli Liang; Hong Zhu; Yaping Zhu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Protects Striatal Cells and Improves Motor Function in Huntington's Disease Models: Role of PAC1 Receptor.

Authors:  Irene Solés-Tarrés; Núria Cabezas-Llobet; Benjamin Lefranc; Jérôme Leprince; Jordi Alberch; David Vaudry; Xavier Xifró
Journal:  Front Pharmacol       Date:  2022-01-28       Impact factor: 5.810

Review 7.  Group I mGluRs in Therapy and Diagnosis of Parkinson's Disease: Focus on mGluR5 Subtype.

Authors:  Shofiul Azam; Md Jakaria; JoonSoo Kim; Jaeyong Ahn; In-Su Kim; Dong-Kug Choi
Journal:  Biomedicines       Date:  2022-04-07

8.  FSC231 alleviates paclitaxel-induced neuralgia by inhibiting the interactions between PICK1 and GluA2 and activates GSK-3β and ERK1/2.

Authors:  Xi Zhang; Jiagao Wang; Ran Ran; Yuchuan Peng; Yun Xiao
Journal:  Brain Behav       Date:  2021-09-28       Impact factor: 2.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.